June 2020
Volume 61, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2020
Early or late switch to intravitreal dexamethasone implant in patients with retinal vein occlusion and poor response to anti-VEGF agents?
Author Affiliations & Notes
  • Eirini Chatziralli
    2nd Department of Ophthalmology, University of Athens, Athens, Greece
  • Stamatina Kabanarou
    Medical Retina Department, Red Cross Hospital, Athens, Greece
  • Eleni Dimitriou
    2nd Department of Ophthalmology, University of Athens, Athens, Greece
  • George Smoustopoulos
    Medical Retina Department, Red Cross Hospital, Athens, Greece
  • George Theodossiadis
    2nd Department of Ophthalmology, University of Athens, Athens, Greece
  • George Bontzos
    Medical Retina Department, Red Cross Hospital, Athens, Greece
  • Panagiotis Theodossiadis
    2nd Department of Ophthalmology, University of Athens, Athens, Greece
  • Footnotes
    Commercial Relationships   Eirini Chatziralli, Allergan (R), Novartis (R); Stamatina Kabanarou, None; Eleni Dimitriou, None; George Smoustopoulos, None; George Theodossiadis, None; George Bontzos, None; Panagiotis Theodossiadis, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2020, Vol.61, 1301. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Eirini Chatziralli, Stamatina Kabanarou, Eleni Dimitriou, George Smoustopoulos, George Theodossiadis, George Bontzos, Panagiotis Theodossiadis; Early or late switch to intravitreal dexamethasone implant in patients with retinal vein occlusion and poor response to anti-VEGF agents?. Invest. Ophthalmol. Vis. Sci. 2020;61(7):1301.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To compare the anatomical and functional outcomes of switching from anti-VEGF agents to intravitreal dexamethasone implant after three or six consecutive monthly injections in patients with retinal vein occlusion (RVO) and poor response to anti-VEGF treatment.

Methods : Patients with treatment-naïve RVO, who showed a poor anatomical response to three or six consecutive intravitreal anti-VEGF injections and received intravitreal dexamethasone implant were enrolled in this prospective study. Patients were divided into two groups as early- (3 injections) and late- (6 injections) switch groups. Best corrected visual acuity (BCVA) and central retinal thickness (CRT) at baseline and at months 3, 6, 9, 12 and 18 were recorded, while the baseline characteristics of patients were also analyzed.

Results : 35 eyes of 35 patients were included in the study. The early-switch group consisted of 17 eyes and the late-switch group consisted of 18 eyes. The mean change in BCVA and CRT did not differ significantly between the two groups at the end of the follow-up period of 18 months compared to baseline (p=0.092 and p=0.201 for BCVA and CRT respectively), although at month 6 the early-switch group presented greater anatomical improvement (p=0.023). Baseline characteristics, which could affect the treatment response and suggest early switch were the presence of hyperreflective foci, the reflectivity and height of intraretinal cysts, the higher CRT and the baseline BCVA.

Conclusions : Although both early- switching and late- switching to intravitreal dexamethasone implant had similar functional outcomes in patients with RVO and poor response to initial anti-VEGF treatment, specific baseline characteristics may suggest early switch to improve better anatomical and functional treatment response, in the context of individualized approach.

This is a 2020 ARVO Annual Meeting abstract.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×